多抗原印迹免疫分析(MAPIA)用于神经囊尾蚴病诊断:秘鲁利马单中心诊断优化与准确性研究
该单中心诊断优化与准确性研究在秘鲁利马开展,先比较五种抗原组合在MAPIA格式中的表现,选出rGP50+rT24H+sTs14组合后检测148份存档血清(40例脑实质型NCC、40例蛛网膜下腔型NCC、68例健康对照)。结果显示该三抗原MAPIA对脑实质型NCC检出39/40(97.5%)、对蛛网膜下腔型检出40/40(100%),68例阴性样本中67例阴性(98.53%),性能与LLGP-EITB相当。
要点
- 三抗原MAPIA检出脑实质型NCC 39/40(97.5%)、蛛网膜下腔型40/40(100%)。
- 68例健康对照中67例阴性(98.53%),特异性表现良好。
- MAPIA简单经济,可克服LLGP-EITB在推广上的障碍。
核心结论
- 使用rGP50+rT24H+sTs14三种抗原的MAPIA是简单、经济的工具,检测NCC特异性抗体的性能与LLGP-EITB相当。
- MAPIA克服了现有EITB LLGP推广应用的障碍,有望在全球范围内使用。
研究设计与样本
- 单中心诊断优化与准确性研究,在秘鲁利马开展。
- 先在既定样本子集中比较五种不同抗原组合在MAPIA格式下的性能,选出最佳组合rGP50+rT24H+sTs14。
- 随后检测148份存档血清样本:40份来自脑实质型NCC个体,40份来自蛛网膜下腔型NCC个体,68份来自无神经系统疾病证据的健康对照。
主要发现
- 三抗原MAPIA检出40例脑实质型NCC中的39例(97.5%)。
- 检出40例蛛网膜下腔型NCC中的40例(100%)。
- 68份阴性样本中67份为阴性(98.53%)。
关键数值与推荐
- 最佳抗原组合为rGP50+rT24H+sTs14。
- 脑实质型NCC灵敏度39/40(97.5%),蛛网膜下腔型NCC灵敏度40/40(100%),阴性样本阴性率67/68(98.53%)。
临床怎么用
- MAPIA使用三种重组和合成抗原,操作简单、经济,可作为NCC特异性抗体检测的候选方法。
- 其性能与LLGP-EITB相当,且克服了后者劳动密集、需复杂设备与专业技术及大量寄生虫材料制备试剂的障碍。
局限性
- 研究为单中心设计,使用存档血清样本,样本量有限。
- 摘要未报告前瞻性验证、跨中心重复性及与其他人群的验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neurocysticercosis (NCC) is the most common helminthic infection of the human central nervous system. The antibody detection assay of choice is the enzyme-linked immunoelectrotransfer blot assay using lentil-lectin purified parasite antigens (LLGP-EITB, Western blot), an immunoassay with exceptional performance in clinical samples. However, its use is mainly restricted to a few research laboratories because the assay is labor-intensive and requires sophisticated equipment, expertise, and large amounts of parasite material for preparation of reagents. We report a new immunoprint assay (MAPIA) that overcomes most of these barriers. We initially compared the performance of five different antigen combinations in a subset of defined samples in the MAPIA format. After selecting the best-performing assay format (a combination of rGP50 + rT24H + sTs14 antigens), 148 archived serum samples were tested, including 40 from individuals with parenchymal NCC, 40 with subarachnoid NCC, and 68 healthy controls with no evidence of neurologic disease. MAPIA using three antigens (rGP50 + rT24H + sTs14) was highly sensitive and specific for detecting antibodies in NCC. It detected 39 out of 40 (97.5%) parenchymal NCC cases and 40/40 (100%) subarachnoid cases and was negative in 67 out of 68 (98.53%) negative samples. MAPIA using three recombinant and synthetic antigens is a simple and economical tool with a performance equivalent to the LLGP-EITB assay for the detection of specific antibodies to NCC. The MAPIA overcomes existing barriers to adoption of the EITG LLGP and is a candidate for worldwide use.
引用
- Toribio L, Guzman C, Noazin S, et al. Multiantigen print immunoassay (MAPIA) for the diagnosis of neurocysticercosis: a single-center diagnostic optimization and accuracy study in Lima, Peru. J Clin Microbiol. 2023. PMID: 37966225. doi:10.1128/jcm.00760-23
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。